Sanofi India Board of Directors

Get the latest insights into the leadership at Sanofi India. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Aditya Narayan Chairman & Ind.Director
Mr. Rodolfo Hrosz Managing Director
Mr. Rachid Ayari WholeTime Director & CFO
Ms. Renee Amonkar Whole Time Director
Mr. Vaibhav Karandikar Non Executive Director
Mrs. Usha Thorat Independent Director
Mr. Rahul Bhatnagar Independent Director

Sanofi India Share price

SANOFI

5094.5

35.50 (-0.69%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:29 IST
BUYSELL
Today's High

5175.50

Today's Low

5075.00

52 Week Low

4902.00

52 Week High

7600.00

The current prices are delayed, login to your account for live prices

Sanofi India FAQs

The board at Sanofi India consists of experienced professionals, including Mr. Aditya Narayan , Mr. Rodolfo Hrosz , and others, overseeing the company’s strategic and corporate governance.

Directors at Sanofi India are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Aditya Narayan is the current chairman at Sanofi India.

Executive directors at Sanofi India are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Sanofi India adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Sanofi India, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.